{"title":"PharmaNews","authors":"","doi":"10.1159/000494396","DOIUrl":"https://doi.org/10.1159/000494396","url":null,"abstract":"Die Christrose fasziniert mit einem umfassenden therapeutischen Potenzial. Entsprechend breit gefächert war das Programm des Helleborus-Symposiums 2018 mit Experten verschiedener Fachrichtungen. Als interdisziplinäre «Schnittmenge» bestätigten sich dabei die antiinflammatorischen und psychosomatischen Effekte der Heilpflanze. Im Fokus stand die integrative Onkologie als Haupteinsatzbereich. Darüber hinaus wurden interessante Behandlungsoptionen in den Bereichen Orthopädie und Neurologie diskutiert.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116749699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Aktualisierte Leitlinie Immunthrombozytopenie","authors":"A. Matzdorff","doi":"10.1159/000492705","DOIUrl":"https://doi.org/10.1159/000492705","url":null,"abstract":"Die Immunthrombozytopenie ist eine seltene Erkrankung. Die Patienten kommen meist mit Petechien und Hämatomen zur Vorstellung, schwere Blutungen sind selten. Daneben klagen viele über eine erhöhte Infektneigung und Erschöpfung (Fatigue). Durch das Labor wird dann eine isolierte Thrombozytopenie bestätigt. Bei allen Patienten muss ein Blutausstrich ärztlich begutachtet werden, wobei die Therapieindikation individuell gestellt und nicht auf die Thrombozytenzahl beschränkt werden sollte. In der Regel gibt man als Erstlinientherapie Kortikosteroide, in der Zweitlinie sind heute Thrombopoetin-Rezeptor-Agonisten etabliert. Eine Splenektomie wird nur noch selten angeboten. Bei vielen Patienten kann ein Anstieg der Thrombozytenzahl und eine dauerhafte Besserung erreicht werden.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129767478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evidenz oder Relevanz - die S3-Leitlinie Kolorektales Karzinom im Alltag","authors":"A. Stein","doi":"10.1159/000493299","DOIUrl":"https://doi.org/10.1159/000493299","url":null,"abstract":"Die S3-Leitlinie Kolorektales Karzinom (KRK) in Ihrer letzten Version von 2013 wurde im November 2017 in aktualisierter Form publiziert, um den umfassenden Änderungen in der Therapie, insbesondere des metastasierten Kolorektalen Karzinoms, Rechnung zu tragen. In der neuen S3-Leitlinie beim KRK wurden einige wichtige und relevante Punkte aufgenommen und verbessert. Insbesondere wurden aktuell prognostische und/oder prädiktive Parameter aufgenommen, die sowohl in der Therapie der lokalisierten Stadien (z.B. extramurale venöse Invasion (EMVI) beim Rektumkarzinom) als auch in der metastasierten Situation (RAS (rat sarcoma)/BRAF (B-rat fibrosarcoma)-Mutationsstatus) eine hohe Relevanz haben. Zudem wurden neue Therapieoptionen in molekularen Subgruppen (HER2 (human epidermal growth factor receptor 2)-Amplifikation oder Mikrosatelliteninstabilität) aufgenommen und der Stellenwert von lokalablativen Maßnahmen gestärkt.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"239 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116118733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Yoga in der supportiven onkologischen Therapie","authors":"H. Cramer","doi":"10.1159/000492908","DOIUrl":"https://doi.org/10.1159/000492908","url":null,"abstract":"Background: Many cancer patients suffer from symptoms of anxiety, depression, and fatigue. Supportive treatments are increasingly used to alleviate distress in cancer. In this study, the effects of yoga on these symptoms are examined. Methods: We performed a randomized controlled study on cancer patients with mixed diagnoses comparing yoga therapy with a waiting list control group. We measured anxiety symptoms with the General Anxiety Disorder (GAD-7) scale, depressive symptoms with the Patient Health Questionnaire-2 (PHQ-2), and fatigue with the European Organisation for Research and Treatment of Cancer Fatigue scale (EORTC QLQ-FA13). Yoga therapy was carried out in weekly sessions of 60 min each for 8 weeks. The program provided restrained body and breathing exercises as well as meditation. The control group did not receive any yoga therapy while on the waiting list. Results: A total of 70 subjects participated in the study. Anxiety was significantly reduced by the yoga therapy in the intervention group compared to the control group (p = 0.005). However, yoga therapy did not show any significant effects on depression (p = 0.21) and fatigue (p = 0.11) compared to the control group. Conclusion: Yoga therapy may be used to alleviate anxiety symptoms in cancer patients and should be the subject of further research.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130653321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Paraneoplastische Syndrome in der Dermatologie - eine Übersicht","authors":"A. Körber","doi":"10.1159/000492708","DOIUrl":"https://doi.org/10.1159/000492708","url":null,"abstract":"A number of paraneoplastic syndromes have been described with gynecological cancers. These syndromes are induced by substances secreted by the tumor or by an immune response triggered by the cancer. Each system of the human body can be affected by different syndromes. Indeed, paraneoplastic syndromes occurring from tumors of the gynecologic tract were found to involve the nervous, ophthalmologic, dermatologic, rheumatologic, endocrine, hematologic and renal systems. These syndromes can manifest before, at the time, or after the diagnosis of cancer. They can also occur at the time of a recurrence. Knowledge about these syndromes is important for physicians caring for patients with cancers, as they can result in severe morbidity and must be treated appropriately. Literature regarding paraneoplastic syndromes associated with tumors of the female genital tract is scattered and the subject has not been reviewed recently. A systematic literature search was thus conducted to identify paraneoplastic syndromes associated with gynecologic cancers. This review focuses on the cancers involved with each paraneoplastic syndrome, and on their pathophysiology, clinical manifestations, possible complications, outcomes, and treatments. As the mainstay of treatment in these conditions is often to address the underlying tumor, it is of upmost importance that physicians be aware of these rare cancer manifestations.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132774103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Patientenzufriedenheit nach Therapie eines Prostatakarzinoms - wann bereuen Patienten ihre Entscheidung?","authors":"Anika Biel","doi":"10.1159/000489735","DOIUrl":"https://doi.org/10.1159/000489735","url":null,"abstract":"Background: Complications of prostate cancer treatments have a substantial impact on the patient's quality of life. We evaluated the prevalence of urinary consequences and factors affecting patient satisfaction and decisional regret after treatment. Methods: A retrospective self-administered questionnaire was sent to all members of the National Association of Prostate Cancer Patients in France. Results: From the 226 completed questionnaires received, the following information was obtained: 110 patients underwent surgery only, 29 received radiotherapy plus hormone therapy, 28 received radiotherapy only, and 49 received other combination treatments. The median follow-up period was 58.1 months. After treatment, the presence of urinary incontinence was reported by 34.5% of patients treated by radical prostatectomy, by 10.3% treated by radiotherapy plus hormone therapy, by 17.8% treated by curitherapy or radiotherapy only, and by 38.7% treated by other combination therapy (p = 0.01). The main reasons for decisional regret were the fact that patients received incomplete information about prostate cancer (40%) and consequences of treatment that affected the urinary system (34%). The information received about cancer was considered complete in 32.3% of the satisfied group and 14.3% of the decisional regret group (p = 0.003) and with regard to urinary incontinence the information received was considered complete in 41.4 and 17.4% respectively (p < 0.01). Conclusions: Urinary consequences of prostate cancer treatment are common and impact the quality of life. Patients need clear information to be able to participate in therapeutic decision-making and to avoid subsequent decisional regret.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122684176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Früherkennung des Lungenkarzinoms durch CT-Screening - Herausforderungen für die europäische Gesundheitspolitik","authors":"W. Schütte, M. Möller","doi":"10.1159/000489909","DOIUrl":"https://doi.org/10.1159/000489909","url":null,"abstract":"Background: Lung cancer kills more Europeans than any other cancer. In 2013, 269,000 citizens of the EU-28 died from this disease. Lung cancer CT screening has the potential to detect lung cancer at an early stage and improve mortality. All of the randomised controlled trials and cohort low-dose CT (LDCT) screening trials across the world have identified very early stage disease (~70%); the majority of these LDCT trial patients were suitable for surgical interventions and had a good clinical outcome. The 10-year survival in CT screen-detected cancer was shown to be even higher than the 5-year survival for early stage disease in clinical practice at 88%. Methods: Setting up of an EU Commission expert group can be done under Article 168(2) of the Treaty on the Functioning of the European Union, to develop policy and recommendation for Lung cancer CT screening. The Expert Group would undertake: (a) assist the Commission in the drawing up policy documents, including guidelines and recommendations; (b) advise the Commission in the implementation of Union actions on screening and suggest improvements to the measures taken; (c) advise the Commission in the monitoring, evaluation and dissemination of the results of measures taken at Union and national level. Results: This EU Expert Group on lung cancer screening should be set up by the EU Commission to support the implementation and suggest recommendations for the lung cancer screening policy by 2019/2020. Conclusion: Reduce lung cancer in Europe by undertaking a well-organised lung cancer CT screening programme.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121272033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Die Heterogenität des Prostatakrebses: Ein praxisorientierter Ansatz","authors":"Y. Tolkach, G. Kristiansen","doi":"10.1159/000489738","DOIUrl":"https://doi.org/10.1159/000489738","url":null,"abstract":"Prostatakrebs ist in nahezu jeder Hinsicht ein beispielhaftes Tumormodell für Heterogenität. Seine klinische, räumliche und morphologische Heterogenität, dividiert durch die hochgradige molekular-genetische Diversität, umreißt die Komplexität dieses Krankheitsbildes im Klinik- und Forschungsumfeld. In dem vorliegenden Review fassen wir die Hauptaspekte der Heterogenität des Prostatakrebses auf verschiedenen Ebenen zusammen, unter besonderer Berücksichtigung der räumlichen Heterogenität innerhalb der Prostata sowie der morphologischen Standardheterogenität in Bezug auf Tumor-Grading und moderne Klassifikationen. Wir befassen uns auch mit der komplexen Frage der molekulargenetischen Heterogenität und diskutieren sie im Zusammenhang mit den aktuellen Erkenntnissen zur genetischen Charakterisierung von Prostatakarzinomen, mit der Heterogenität zwischen Patienten und Tumoren (multifokale Erkrankung) sowie der Heterogenität innerhalb eines Tumors, mit der Tumorklonalität und mit der Metastasierung. Die möglichen Konsequenzen für Klinik und Forschung werden zusammengefasst und dazu verwendet, die relevantesten Probleme zu diskutieren, die sich aus der extremen Heterogenität des Prostatakrebses ergeben. Übersetzung aus Tolkach Y, Kristiansen G: Pathobiology 2018;85:108-116.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129021793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
